Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 698 results for must

  1. Epilepsy: seizure free in preceding 12 months (IND145)

    This indicator covers the percentage of patients aged 18 or over on drug treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM110

  2. Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

    Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

  3. OpenAthens eligibility

    Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.

  4. Bimekizumab for treating active psoriatic arthritis (TA916)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.

  5. Permission to use NICE content for artificial intelligence (AI) purposes

    relevant copyright owner. If you want to use our content for AI purposes, you must complete the AI request form. Loading form, please...

  6. Tirzepatide for managing overweight and obesity (TA1026)

    Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.

  7. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

  8. Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

    Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

  9. Depression and anxiety: biopsychosocial assessment at diagnosis (IND103)

    This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have had a bio-psychosocial assessment by the point of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM49

  10. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (HTG535)

    Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.

  11. Use of NICE content in the UK

    Note: If you plan to use our content in an international setting, you must submit the International use of NICE content form . Requests...

  12. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  13. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

  14. Nusinersen for treating spinal muscular atrophy (TA588)

    Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.

  15. Charging procedure

    Charging procedure for NICE technology appraisal and highly specialised technologies evaluations